Results 151 to 160 of about 24,468 (197)

Medroxyprogesterone acetate versus ganirelix in oocyte donation: a randomized controlled trial.

Human Reproduction, 2019
STUDY QUESTION Is oral medroxiprogesterone acetate (MPA) non-inferior compared to ganirelix with respect to the number of mature oocytes (MII) retrieved at ovum pick-up (OPU) in oocyte donation cycles?
R. Beguería, D. Garcia, R. Vassena, Amelia Rodríguez   +3 more
semanticscholar   +1 more source

Side Effects and Health Benefits of Depot Medroxyprogesterone Acetate: A Systematic Review.

Obstetrics and Gynecology, 2019
OBJECTIVE Counseling about potential side effects and health benefits of contraceptive methods could facilitate continued method use and method satisfaction, yet no evidence-based compilation of side effects and benefits exists to aid such counseling ...
Shokoufeh Dianat, E. Fox, K. Ahrens, U. Upadhyay, V. Zlidar, M. Gallo, R. Stidd, S. Moskosky, C. Dehlendorf   +8 more
semanticscholar   +1 more source

Medroxyprogesterone

Reactions Weekly, 1992
  +4 more sources

Medroxyprogesterone

Reactions Weekly, 2017
  +5 more sources

Medroxyprogesterone

Reactions Weekly, 2018
  +5 more sources

Medroxyprogesterone

Reactions Weekly, 1991
  +4 more sources

Efficacy of medroxyprogesterone acetate treatment and retreatment for atypical endometrial hyperplasia and endometrial cancer

The journal of obstetrics and gynaecology research, 2018
S. Tamauchi, H. Kajiyama, Fumi Utsumi, Shiro Suzuki, K. Niimi, J. Sakata, M. Mizuno, K. Shibata, F. Kikkawa   +8 more
semanticscholar   +1 more source